Skip to main content
AAN.com
Peripheral Nerve Disorders
April 18, 2017
Free Access

A Prospective Study of Benign Fasciculation Syndrome (S45.007)

April 18, 2017 issue
88 (16_supplement)

Abstract

Objective:

To further elucidate the natural history of BFS.

Background:

Benign fasciculations are common in the general population, occurring in about 70% of healthy individuals. They are almost never associated with a serious neuromuscular disorder. However, they appear to be a cause of anxiety, particularly among those in the medical field. To our knowledge, no prospective study has been conducted on BFS patients.

Design/Methods:

This is a two-year prospective study. Patients seen for fasciculations in the absence of weakness, atrophy, or other neurologic symptoms were eligible. Patients were diagnosed based on otherwise normal examinations and normal EMGs except for fasciculation potentials. To date, 34 patients have been enrolled. Interviews were conducted at diagnosis and months 1, 3, 6, 12, and 24.

Results:

34.4% were female. 34.4% had a medical background. 29.4% had a diagnosed psychiatric disorder. However, only 8.8% were on an SSRI and 17.6% on a benzodiazepine. Subjective weakness was reported by 35.3%. Many patients reported sensory symptoms (47.1% numbness, 70.6% had tingling). Cramps were present in 64.7%. Based on the data we obtained over two years, we constructed Kaplan-Meier survival curves to predict the duration of each symptom. At 12 months, 95% of patients still had fasciculations, 25% still reported subjective weakness, 27.5% still had numbness, 57.9% still had tingling, and 62.6% still reported cramps. No patients developed motor neuron disease.

Conclusions:

Despite its benign natural history, BFS is a source of high morbidity for patients, both physically and psychologically. At two years, fasciculations resolved in only 5% of patients. Most still experienced subjective weakness, sensory symptoms, and cramps. Symptoms did not seem to resolve with reassurance. However, most of these patients were not treated for anxiety. It remains to be seen if BFS symptoms remit with treatment of anxiety.
Disclosure: Dr. Filippakis has nothing to disclose. Dr. Jara has nothing to disclose. Dr. Ventura has nothing to disclose. Dr. Ruthazer has nothing to disclose. Dr. Russell has received royalty payments from McGraw Hill. Dr. Ho has nothing to disclose.

Information & Authors

Information

Published In

Neurology®
Volume 88Number 16_supplementApril 18, 2017

Publication History

Published online: April 18, 2017
Published in print: April 18, 2017

Authors

Affiliations & Disclosures

Alexandra Filippakis
Tufts Medical Center Boston MA United States
Jordan Jara
Lahey Hospital and Medical Center Burlington MA United States
Nick Ventura
Lahey Hospital and Medical Center Burlington MA United States
Robin Ruthazer
Tufts Medical Center Boston MA United States
James Russell
Lahey Hospital and Medical Center Burlington MA United States
Doreen Ho
Lahey Hospital and Medical Center Burlington MA United States

Metrics & Citations

Metrics

Citations

Download Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Select your manager software from the list below and click Download.

Cited By

View Options

View options

Get Access

Login options

Check if you have access through your login credentials or your institution to get full access on this article.

Personal login Institutional Login
Purchase Options

Purchase this article to get full access to it.

Purchase Access, $39 for 24hr of access

Media

Figures

Other

Tables

Share

Share

Share article link

Share